Neil Kumar - 27 Mar 2026 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
31 Mar 2026, 16:13:50 UTC
Prior SEC filing
19 Mar 2026
Next SEC filing
13 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Courtney Phillips, as attorney-in-fact

Key filing fact

Neil Kumar filed Form 4 for Maze Therapeutics, Inc. (MAZE) on 31 Mar 2026.

Key facts

  • This page summarizes Neil Kumar's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 31 Mar 2026, 16:13.

Change

  • Previous filing in this sequence was filed on 19 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742485 Primary reporting owner

Kumar Neil

Relationship
Director
Address
C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Signature
/s/ Courtney Phillips, as attorney-in-fact
Signature date
31 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MAZE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+33,417
Change %
Price
$0.000000*
Shares after
33,417
Date
27 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
33,417
Exercise price
$30.38
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .